A RADICAL NEW WAY TO TREAT SOLID TUMORS
Powerful & precise T cell therapy that attacks
solid tumors while sparing normal cells
Innovating new treatments for solid tumors
A2 Bio proprietary Tmod™ platform has the ability to absolutely distinguish tumor from normal cells
This is accomplished by integrating multiple signals, overcoming the limits of conventional single-target therapies and by exploiting common, specific gene losses only found in tumor cells
The Tmod™ precision-targeting cell therapy platform aims the powerful armaments of immune cells at tumors, while protecting normal cells. A2 Bio has a first-mover advantage in exploiting the loss of genetic material in cancer cells.
Modular and flexible, our platform is designed to enable a broad pipeline of both autologous and allogeneic cell products that access a large array of unexploited therapeutic targets, including targets previously constrained by toxicity.
Led by a management team with over 90 years of combined experience in cell therapy and biotechnology, A2 Bio is guided by our science and relentless focus to bring forward bold solutions that alter the course of cancer treatment.
January 13, 2021
Tempus Announces Companion Diagnostic Collaboration with A2 Biotherapeutics
December 23, 2020
A2 Biotherapeutics Enters into Collaboration Agreement with Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers
October 6, 2020
A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of Its Potentially Transformative Selective Tumor Cell Therapeutics